Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bytzer

Showing results (41-50 of 104) with videos related to

Pageof 11
Sort By:
Scandinavian Journal of Gastroenterology|November 1, 1992
Prediction of major pathologic conditions in dyspeptic patients referred for endoscopy. A prospective validation study of a scoring systemP Bytzer, O B Schaffalitzky de Muckadell
Ugeskrift for Laeger|April 11, 1994
[Is the clinical classification of dyspepsia patients worth the effort?]O B Schaffalitzky de Muckadell, P Bytzer
Alimentary Pharmacology & Therapeutics|April 26, 2017
Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndromeL R Krogsgaard, M Lyngesen, P Bytzer
Experimental Cell Research|October 1, 1981
Membrane retrieval in non-exocytic and exocytic rat peritoneal mast cellsE H Nielsen, J Clausen, P Bytzer
Neurogastroenterology and Motility|March 17, 2012
The Rome II and Rome III criteria identify the same subtype-populations in irritable bowel syndrome: agreement depends on the method used for symptom reportA L Engsbro, M Simrén, P Bytzer
Scandinavian Journal of Gastroenterology|August 1, 1986
Symptomatic recurrence of healed duodenal and prepyloric ulcers after treatment with ranitidine or high-dose antacid. A 1-year follow-up studyP Bytzer, K Lauritsen, J Rask-Madsen
Alimentary Pharmacology & Therapeutics|August 10, 2004
Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial--is gastro-oesophageal reflux important?L G Madsen, L Wallin, P Bytzer
Alimentary Pharmacology & Therapeutics|July 6, 2017
Letter: bias in clinical trials of the symptomatic effects of the low FODMAP diet for irritable bowel syndrome-getting the facts right. Authors' replyL R Krogsgaard, M Lyngesen, P Bytzer
Alimentary Pharmacology & Therapeutics|August 5, 2015
Editorial: anti-secretory therapy prior to anti-reflux surgery. Does dose matter? Authors' replyA Lødrup, A Pottegård, J Hallas, et al.
Scandinavian Journal of Gastroenterology|June 13, 2002
Treatment of non-ulcer dyspepsia: are prokinetics effective?P Bytzer, J Møller, O Schaffalitzky de Muckadell
Pageof 11

Showing results (41-50 of 104) with videos related to

Sort By:
Pageof 11
Scandinavian Journal of Gastroenterology|November 1, 1992
Prediction of major pathologic conditions in dyspeptic patients referred for endoscopy. A prospective validation study of a scoring systemP Bytzer, O B Schaffalitzky de Muckadell
Ugeskrift for Laeger|April 11, 1994
[Is the clinical classification of dyspepsia patients worth the effort?]O B Schaffalitzky de Muckadell, P Bytzer
Alimentary Pharmacology & Therapeutics|April 26, 2017
Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndromeL R Krogsgaard, M Lyngesen, P Bytzer
Experimental Cell Research|October 1, 1981
Membrane retrieval in non-exocytic and exocytic rat peritoneal mast cellsE H Nielsen, J Clausen, P Bytzer
Neurogastroenterology and Motility|March 17, 2012
The Rome II and Rome III criteria identify the same subtype-populations in irritable bowel syndrome: agreement depends on the method used for symptom reportA L Engsbro, M Simrén, P Bytzer
Scandinavian Journal of Gastroenterology|August 1, 1986
Symptomatic recurrence of healed duodenal and prepyloric ulcers after treatment with ranitidine or high-dose antacid. A 1-year follow-up studyP Bytzer, K Lauritsen, J Rask-Madsen
Alimentary Pharmacology & Therapeutics|August 10, 2004
Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial--is gastro-oesophageal reflux important?L G Madsen, L Wallin, P Bytzer
Alimentary Pharmacology & Therapeutics|July 6, 2017
Letter: bias in clinical trials of the symptomatic effects of the low FODMAP diet for irritable bowel syndrome-getting the facts right. Authors' replyL R Krogsgaard, M Lyngesen, P Bytzer
Alimentary Pharmacology & Therapeutics|August 5, 2015
Editorial: anti-secretory therapy prior to anti-reflux surgery. Does dose matter? Authors' replyA Lødrup, A Pottegård, J Hallas, et al.
Scandinavian Journal of Gastroenterology|June 13, 2002
Treatment of non-ulcer dyspepsia: are prokinetics effective?P Bytzer, J Møller, O Schaffalitzky de Muckadell
Pageof 11